Infant Bacterial Therapeutics Narrows Loss as FDA Backs Accelerated Path for IBP-9414

Infant Bacterial Therapeutics AB ( ($SE:IBT.B) ) has issued an announcement.

Infant Bacterial Therapeutics reported no net sales and a narrowed operating loss for 2025, reflecting its continued status as a development-stage company while it advances its lead candidate IBP-9414 toward commercialization. During the year, IBP-9414 received Breakthrough Therapy Designation from the FDA, the Phase 3 “Connection Study” clinical report was submitted, and the FDA encouraged the company to pursue an accelerated marketing approval path, with ongoing work on a post-launch clinical study and validation of commercial-scale manufacturing through new production partnerships in Germany and the Netherlands, positioning the firm for a potential U.S. market entry despite a tight timeline.

The most recent analyst rating on ($SE:IBT.B) stock is a Hold with a SEK48.00 price target. To see the full list of analyst forecasts on Infant Bacterial Therapeutics AB stock, see the SE:IBT.B Stock Forecast page.

More about Infant Bacterial Therapeutics AB

Infant Bacterial Therapeutics AB is a Swedish biopharmaceutical company focused on developing microbiome-based drug candidates for vulnerable infants, with its lead product, IBP-9414, targeting the reduction of gastrointestinal-related mortality in premature babies. The company operates in the neonatal care space, seeking regulatory approvals primarily in the U.S. market and building a commercial manufacturing network in Europe to support future product launch.

Average Trading Volume: 10,072

Technical Sentiment Signal: Sell

Current Market Cap: SEK633.2M

For detailed information about IBT.B stock, go to TipRanks’ Stock Analysis page.